Slide 1: AdAlta presentation at Bioshares Biotech Summit
10 May 2022 ASX Announcement AdAlta presentation at Bioshares Biotech Summit MELBOURNE Australia, 10 May 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr Ti
Slide 2: About AdAlta
Notes to Editors About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody p
Slide 3: Developing i-body enabled drugs for challenging diseases
Developing i-body enabled drugs for challenging diseases Tim Oldham PhD, CEO and Managing Director BioShares Conference, 11 May 2022
Slide 4: Disclaimer
BIOSHARES CONFERENCE – MAY 2022 2 Disclaimer Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and capital invested. AdAlta po
Slide 5: AdAlta at a glance
BIOSHARES CONFERENCE – MAY 2022 3 AdAlta at a glance Building out pipeline Targeting 10 internal and external programs by end 2023 Immuno-oncology: two co-development collaborations 1. GZMB PET imaging agent with GE Healthcare: US$6.4b market 2. i-body enabled CAR-T with Carina Biotech: US$20b marke
Slide 6: Today's objective: explore AdAlta's approach to "big" drug development decisions
BIOSHARES CONFERENCE – MAY 2022 4 Today’s objective: explore AdAlta’s approach to “big” drug development decisions Realising novel i-body platform potential Focus, investment in platform, multiple “proof of principle” examples, balanced pipeline Taking big decisions Align with strategy, deliver targ
Slide 7: Maximising i-body platform potential
Maximising i-body platform potential
Slide 8: i-bodies: a powerful drug discovery engine for next generation protein therapeutics
BIOSHARES CONFERENCE – MAY 2022 6 i-bodies: a powerful drug discovery engine for next generation protein therapeutics 1 2 3 AdAlta’s i-body library has 1010 unique i-bodies Shark single domain antibody A human protein that is structurally i-bodies mimic the (sdAb): small size and long equivalent to
Slide 9: Focus is very important for platform companies facing large opportunities
BIOSHARES CONFERENCE – MAY 2022 7 Focus is very important for platform companies facing large opportunities Benefits of focus AdAlta’s current focus choices Organisation • Repeat projects build experience, expertise expertise • Defines required skills and knowledge Business model Early stage drug R&
Slide 10: Requirements to move beyond a single product and realise platform value
BIOSHARES CONFERENCE – MAY 2022 8 Requirements to move beyond a single product and realise platform value AdAlta in 2022 Continuous platform Expanding library of proof of improvements principle “use cases” AdAlta in 2019 i-body2.0 program 3 product formats Expanding library of Shorter screening 2 pa
Slide 11: Taking big decisions during i-body drug development
Taking big decisions during i-body drug development 9
Slide 12: Lenses for making big decisions
BIOSHARES CONFERENCE – MAY 2022 10 Lenses for making big decisions Strategic alignment Target product profile Efficacy, IP safety Minimum viable product Cost/ Core Delivery supply Decision? Value creation/ ROI Data, information, insight Option creation Risk reduction
Slide 13: Recent "big" decisions at AdAlta
BIOSHARES CONFERENCE – MAY 2022 11 Recent “big” decisions at AdAlta Case study in next section Decision Strategic Target product Data & Value creation alignment profile information • Defining focus for platform +++ + ++ +++ • Selecting targets for pipeline ++ ++ +++ +++ • Expanding team, pipeline ++
Slide 14: A big decision case study: inhaled AD-214
A big decision case study: inhaled AD-214 12
Slide 15: AD-214 | Completed Phase I, preparing superior inhalation format for Phase II
BIOSHARES CONFERENCE – MAY 2022 13 AD-214 | Completed Phase I, preparing superior inhalation format for Phase II New data, additional time, and knowledge of minimum viable and optimum target product profiles gave AdAlta the opportunity to consider investment in an inhaled form of AD-214 alongside th
Slide 16: Inhalation precedents | IPF and protein therapeutics
BIOSHARES CONFERENCE – MAY 2022 14 Inhalation precedents | IPF and protein therapeutics Information from precedents and experts informed initial feasibility and selection of risk mitigation strategies Inhalation used regularly in IPF and Substantial number of biologics in Off-the-shelf devices for o
Slide 17: AdAlta's approach to the factors to consider when developing inhaled biologics
BIOSHARES CONFERENCE – MAY 2022 15 AdAlta’s approach to the factors to consider when developing inhaled biologics Factor AdAlta approach for AD-214 decision knowledge Extent of current Benefit of inhaled route of • Improves IPF target product profile administration • Continued IV investment adds opt
Slide 18: Inhaled AD-214 | Milestones to gain new knowledge and opportunities in 2022
BIOSHARES CONFERENCE – MAY 2022 16 Inhaled AD-214 | Milestones to gain new knowledge and opportunities in 2022 June 2022 Through mid CY 2022 September 2022 quarter December 2022 quarter quarter • Antifibrotic effects in • Efficacy in bleomycin cultured human lung mouse model* • Preparation for inhal
Slide 19: I/O assets | Other AdAlta milestones and opportunities in 2022
BIOSHARES CONFERENCE – MAY 2022 17 I/O assets | Other AdAlta milestones and opportunities in 2022 Through mid CY Through mid CY September 2022 December 2022 2022 2022 quarter quarter iCAR-T Target A • Initial in vitro • in vitro cancer • GZMB iPET cell killing cancer cell killing imaging agent • iCA
Slide 20: Contact: Tim Oldham, CEO and Managing Director
Contact: Tim Oldham, CEO and Managing Director enquiries@adalta.com.au www.adalta.com.au